163 related articles for article (PubMed ID: 27352830)
1. No evidence of disease activity in multiple sclerosis patients.
Matta AP; Nascimento OJ; Ferreira AC; Magalhães TN; Benevides TP; Kirmse A; Dib JG; Cal H; Orsini M; Araujo LM
Expert Rev Neurother; 2016 Nov; 16(11):1279-1284. PubMed ID: 27352830
[TBL] [Abstract][Full Text] [Related]
2. Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity.
Yokote H; Kamata T; Toru S; Sanjo N; Yokota T
Neurol Sci; 2018 Oct; 39(10):1713-1716. PubMed ID: 29974307
[TBL] [Abstract][Full Text] [Related]
3. No evidence of disease activity in multiple sclerosis: Implications on cognition and brain atrophy.
Damasceno A; Damasceno BP; Cendes F
Mult Scler; 2016 Jan; 22(1):64-72. PubMed ID: 26432855
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
5. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?
Uher T; Havrdova E; Sobisek L; Krasensky J; Vaneckova M; Seidl Z; Tyblova M; Ramasamy D; Zivadinov R; Horakova D
Mult Scler; 2017 Feb; 23(2):242-252. PubMed ID: 27230790
[TBL] [Abstract][Full Text] [Related]
6. "No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
Mayssam EN; Eid C; Khoury SJ; Hannoun S
Mult Scler Relat Disord; 2020 May; 40():101935. PubMed ID: 31951861
[TBL] [Abstract][Full Text] [Related]
7. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis.
Giovannoni G; Tomic D; Bright JR; Havrdová E
Mult Scler; 2017 Aug; 23(9):1179-1187. PubMed ID: 28381105
[TBL] [Abstract][Full Text] [Related]
8. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
[TBL] [Abstract][Full Text] [Related]
9. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?
Hegen H; Bsteh G; Berger T
Eur J Neurol; 2018 Sep; 25(9):1107-e101. PubMed ID: 29687559
[TBL] [Abstract][Full Text] [Related]
10. The evolution of "No Evidence of Disease Activity" in multiple sclerosis.
Lu G; Beadnall HN; Barton J; Hardy TA; Wang C; Barnett MH
Mult Scler Relat Disord; 2018 Feb; 20():231-238. PubMed ID: 29579629
[TBL] [Abstract][Full Text] [Related]
11. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni G; Turner B; Gnanapavan S; Offiah C; Schmierer K; Marta M
Mult Scler Relat Disord; 2015 Jul; 4(4):329-33. PubMed ID: 26195051
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.
Zivadinov R; Jakimovski D; Gandhi S; Ahmed R; Dwyer MG; Horakova D; Weinstock-Guttman B; Benedict RR; Vaneckova M; Barnett M; Bergsland N
Expert Rev Neurother; 2016 Jul; 16(7):777-93. PubMed ID: 27105209
[TBL] [Abstract][Full Text] [Related]
13. NEDA treatment target? No evident disease activity as an actionable outcome in practice.
Parks NE; Flanagan EP; Lucchinetti CF; Wingerchuk DM
J Neurol Sci; 2017 Dec; 383():31-34. PubMed ID: 29246616
[TBL] [Abstract][Full Text] [Related]
14. Optimizing treatment success in multiple sclerosis.
Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
[TBL] [Abstract][Full Text] [Related]
15. Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B
Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800
[TBL] [Abstract][Full Text] [Related]
16. MRI evaluation of grey matter atrophy and disease course in multiple sclerosis: an overview of current knowledge.
Jacobsen CO; Farbu E
Acta Neurol Scand Suppl; 2014; (198):32-6. PubMed ID: 24588504
[TBL] [Abstract][Full Text] [Related]
17. Is physical exercise a multiple sclerosis disease modifying treatment?
Motl RW; Pilutti LA
Expert Rev Neurother; 2016 Aug; 16(8):951-60. PubMed ID: 27219279
[TBL] [Abstract][Full Text] [Related]
18. Visual field impairment captures disease burden in multiple sclerosis.
Ortiz-Perez S; Andorra M; Sanchez-Dalmau B; Torres-Torres R; Calbet D; Lampert EJ; Alba-Arbalat S; Guerrero-Zamora AM; Zubizarreta I; Sola-Valls N; Llufriu S; Sepúlveda M; Saiz A; Villoslada P; Martinez-Lapiscina EH
J Neurol; 2016 Apr; 263(4):695-702. PubMed ID: 26860093
[TBL] [Abstract][Full Text] [Related]
19. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability.
Charil A; Dagher A; Lerch JP; Zijdenbos AP; Worsley KJ; Evans AC
Neuroimage; 2007 Jan; 34(2):509-17. PubMed ID: 17112743
[TBL] [Abstract][Full Text] [Related]
20. Cognitive event-related potentials in multiple sclerosis: Correlation with MRI and neuropsychological findings.
Kimiskidis VK; Papaliagkas V; Sotirakoglou K; Kouvatsou ZK; Kapina VK; Papadaki E; Tsimourtou V; Masoura E; Kazis DA; Papayiannopoulos S; Geroukis T; Bostanjopoulou S
Mult Scler Relat Disord; 2016 Nov; 10():192-197. PubMed ID: 27919489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
